Pharmacogenetics in Psychiatry: An Update on Clinical Usability

Ron H N van Schaik; Daniel J Müller; Alessandro Serretti; Magnus Ingelman-Sundberg

doi:10.3389/fphar.2020.575540

Pharmacogenetics in Psychiatry: An Update on Clinical Usability

Front Pharmacol. 2020 Sep 11:11:575540. doi: 10.3389/fphar.2020.575540. eCollection 2020.

Authors

Ron H N van Schaik¹, Daniel J Müller^{2

3}, Alessandro Serretti⁴, Magnus Ingelman-Sundberg⁵

Affiliations

¹ Department of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
² Pharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
³ Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁴ Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.
⁵ Pharmacogenetics Section, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Abstract

Using pharmacogenetics in guiding drug therapy experiences a steady increase in uptake, although still leads to discussions as to its clinical use. Psychiatry constitutes a field where pharmacogenomic testing might help in guiding drug therapy. To address current challenges, this minireview provides an update regarding genotyping (SNP analysis/arrays/NGS), structural variant detection (star-alleles/CNVs/hybrid alleles), genotype-to-phenotype translations, cost-effectiveness, and actionability of results (FDA/CPIC/PharmGKB) regarding clinical importance of pre-emptive pharmacogenomic testing for prescription of antidepressants and antipsychotics.

Keywords: CYP2C19; CYP2D6; antidepressant; cytochrome P450; depression; pharmacogenetics; psychiatry.

Publication types

Review